A newly synthetic chromium complex-Chromium (d-phenylalanine)3 activates AMP-activated protein kinase and stimulates glucose transport

Biochemical Pharmacology

Volumn 77, Issue 6, 2009, Pages 1002-1010

  Zhao, Peng ^a,b   Wang, Jingying ^b   Ma, Heng ^b   Xiao, Yao ^b   He, Leilei ^b   Tong, Chao ^b   Wang, Zhenhua ^c   Zheng, Qiusheng ^c   Dolence, E Kurt ^b   Nair, Sreejayan ^b   Ren, Jun ^b   Li, Ji ^b,c  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^c SHIHEZI UNIVERSITY   (China)

Author keywords

AMP activated protein kinase; Chromium; Glucose transport; Insulin resistance

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CHROMIUM (DEXTRO PHENYLALANINE) 3; CHROMIUM DERIVATIVE; DEOXYGLUCOSE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SYNTHESIS; GLUCOSE TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSULIN SENSITIVITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CHROMIUM COMPOUNDS; ENZYME ACTIVATION; GLUCOSE; INSULIN RESISTANCE; MICE; MYOCYTES, CARDIAC; ORGANOMETALLIC COMPOUNDS; PHENYLALANINE; RATS; SIGNAL TRANSDUCTION;

EID: 60649110428     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.11.018     Document Type: Article

References (54)

1. 3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett 579 (2005) 1458-1464
2. Striffler J.S., Polansky M.M., and Anderson R.A. Overproduction of insulin in the chromium-deficient rat. Metabolism 48 (1999) 1063-1068
3. Morris B.W., Kouta S., Robinson R., MacNeil S., and Heller S. Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Diabet Med 17 (2000) 684-685
4. Horvath E.M., Tackett L., McCarthy A.M., Raman P., Brozinick J.T., and Elmendorf J.S. Antidiabetogenic effects of chromium mitigate hyperinsulinemia-induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance. Mol Endocrinol 22 (2008) 937-950
5. 3. J Inorg Biochem 100 (2006) 1187-1193
6. 3 improves obesity-induced cardiac contractile defect in ob/ob mice. Obesity (Silver Spring) 15 (2007) 2699-2711
7. Sreejayan N., Dong F., Kandadi M.R., Yang X., and Ren J. Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. Obesity (Silver Spring) 16 (2008) 1331-1337
8. Hardie D.G., Scott J.W., Pan D.A., and Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546 (2003) 113-120
9. Kemp B.E., Stapleton D., Campbell D.J., Chen Z.P., Murthy S., Walter M., et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 31 (2003) 162-168
10. Hallows K.R., McCane J.E., Kemp B.E., Witters L.A., and Foskett J.K. Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. J Biol Chem 278 (2003) 998-1004
11. Woods A., Azzout-Marniche D., Foretz M., Stein S.C., Lemarchand P., Ferre P., et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 20 (2000) 6704-6711
12. Kudo N., Barr A.J., Barr R.L., Desai S., and Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270 (1995) 17513-17520
13. Kudo N., Gillespie J.G., Kung L., Witters L.A., Schulz R., Clanachan A.S., et al. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1301 (1996) 67-75
14. Winder W.W., and Hardie D.G. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 270 (1996) EE299-EE304
15. Rutter G.A., Da Silva Xavier G., and Leclerc I. Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 375 (2003) 1-16
16. Marsin A.S., Bertrand L., Rider M.H., Deprez J., Beauloye C., Vincent M.F., et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 10 (2000) 1247-1255
17. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443 (1999) 285-289
18. Chen Z.P., McConell G.K., Michell B.J., Snow R.J., Canny B.J., and Kemp B.E. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 279 (2000) E1202-E1206
19. Morrow V.A., Foufelle F., Connell J.M., Petrie J.R., Gould G.W., and Salt I.P. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 278 (2003) 31629-31639
20. Browne S.E., Ayata C., Huang P.L., Moskowitz M.A., and Beal M.F. The cerebral metabolic consequences of nitric oxide synthase deficiency: glucose utilization in endothelial and neuronal nitric oxide synthase null mice. J Cereb Blood Flow Metab 19 (1999) 144-148
21. Duplain H., Burcelin R., Sartori C., Cook S., Egli M., Lepori M., et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104 (2001) 342-345
22. Vicent D., Ilany J., Kondo T., Naruse K., Fisher S.J., Kisanuki Y.Y., et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 111 (2003) 1373-1380
23. Turdi S., Li Q., Lopez F.L., and Ren J. Catalase alleviates cardiomyocyte dysfunction in diabetes: role of Akt, Forkhead transcriptional factor and silent information regulator 2. Life Sci 81 (2007) 895-905
24. Smiley S.T., Reers M., Mottola-Hartshorn C., Lin M., Chen A., Smith T.W., et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 88 (1991) 3671-3675
25. Konrad D., Rudich A., Bilan P.J., Patel N., Richardson C., Witters L.A., et al. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 48 (2005) 954-966
26. Li J., Coven D.L., Miller E.J., Hu X., Young M.E., Carling D., et al. Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart. Am J Physiol Heart Circ Physiol 291 (2006) H1927-H1934
27. Li J., Miller E.J., Ninomiya-Tsuji J., Russell III R.R., and Young L.H. AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ Res 97 (2005) 872-879
28. Zong H., Ren J.M., Young L.H., Pypaert M., Mu J., Birnbaum M.J., et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 99 (2002) 15983-15987
29. Li J., Hu X., Selvakumar P., Russell III R.R., Cushman S.W., Holman G.D., et al. Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. Am J Physiol Endocrinol Metab 287 (2004) E834-E841
30. Young L.H. AMP-activated protein kinase conducts the ischemic stress response orchestra. Circulation 117 (2008) 832-840
31. Russell III R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114 (2004) 495-503
32. Sellevold O.F., Jynge P., and Aarstad K. High performance liquid chromatography: a rapid isocratic method for determination of creatine compounds and adenine nucleotides in myocardial tissue. J Mol Cell Cardiol 18 (1986) 517-527
33. Young L.H., Li J., Baron S.J., and Russell R.R. AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc Med 15 (2005) 110-118
34. Chen G., Liu P., Pattar G.R., Tackett L., Bhonagiri P., Strawbridge A.B., et al. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 20 (2006) 857-870
35. Pattar G.R., Tackett L., Liu P., and Elmendorf J.S. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res 610 (2006) 93-100
36. Freund H., Atamian S., and Fischer J.E. Chromium deficiency during total parenteral nutrition. JAMA 241 (1979) 496-498
37. Brown R.O., Forloines-Lynn S., Cross R.E., and Heizer W.D. Chromium deficiency after long-term total parenteral nutrition. Dig Dis Sci 31 (1986) 661-664
38. Verhage A.H., Cheong W.K., and Jeejeebhoy K.N. Neurologic symptoms due to possible chromium deficiency in long-term parenteral nutrition that closely mimic metronidazole-induced syndromes. JPEN J Parenter Enteral Nutr 20 (1996) 123-127
39. Morris B.W., MacNeil S., Hardisty C.A., Heller S., Burgin C., and Gray T.A. Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol 13 (1999) 57-61
40. Anderson R.A. Effects of chromium on body composition and weight loss. Nutr Rev 56 (1998) 266-270
41. Anderson R.A. Chromium, glucose intolerance and diabetes. J Am Coll Nutr 17 (1998) 548-555
42. Kuller L.H., Velentgas P., Barzilay J., Beauchamp N.J., O'Leary D.H., and Savage P.J. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol 20 (2000) 823-829
43. Temelkova-Kurktschiev T.S., Koehler C., Henkel E., Leonhardt W., Fuecker K., and Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23 (2000) 1830-1834
44. Nakamura Y., Saitoh S., Takagi S., Ohnishi H., Chiba Y., Kato N., et al. Impact of abnormal glucose tolerance, hypertension and other risk factors on coronary artery disease. Circ J 71 (2007) 20-25
45. Miller E.J., Li J., Leng L., McDonald C., Atsumi T., Bucala R., et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451 (2008) 578-582
46. Thirunavukkarasu M., Penumathsa S.V., Juhasz B., Zhan L., Cordis G., Altaf E., et al. Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 291 (2006) H820-H826
47. Baron S.J., Li J., Russell III R.R., Neumann D., Miller E.J., Tuerk R., et al. Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circ Res 96 (2005) 337-345
48. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2 (2005) 9-19
49. Woods A., Dickerson K., Heath R., Hong S.P., Momcilovic M., Johnstone S.R., et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2 (2005) 21-33
50. Dazy M., Beraud E., Cotelle S., Meux E., Masfaraud J.F., and Ferard J.F. Antioxidant enzyme activities as affected by trivalent and hexavalent chromium species in Fontinalis antipyretica Hedw. Chemosphere 73 (2008) 281-290
51. Slodzinski M.K., Aon M.A., and O'Rourke B. Glutathione oxidation as a trigger of mitochondrial depolarization and oscillation in intact hearts. J Mol Cell Cardiol (2008)
52. Cool B., Zinker B., Chiou W., Kifle L., Cao N., Perham M., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3 (2006) 403-416
53. Musi N., Hayashi T., Fujii N., Hirshman M.F., Witters L.A., and Goodyear L.J. AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. Am J Physiol Endocrinol Metab 280 (2001) E677-E684
54. Culmsee C., Monnig J., Kemp B.E., and Mattson M.P. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci 17 (2001) 45-58